Virus-specific CD8⁺ lymphocyte count does not discriminate between HCT patients with different CMV outcomes. CMV(pp65)-specific CD8⁺ T-cell counts are shown. (A) CMV-specific CD8⁺ T cells as a function of absolute lymphocyte count, for patients with and without CMV reactivation. Y-axis corresponds to log₁₀ scale. (B) The 100-day cumulative incidence of CMV reactivation (any DNAemia) by CMV-specific CD8⁺ T-cell count above (n = 17) or below (n = 19) the median (150 cells per microliter). (C) The proportion of CMV-responding cells (by producing any cytokine in response to in vitro stimulation with CMV-pp65) within the CD8⁺ T-cell compartment. T-cell counts were measured on day +30. Median with IQR is shown for each group. P value in panel A corresponds to comparison between groups by using Mann-Whitney U test. P value in panel B corresponds to comparison between groups by using Log-rank test. P value for the Kruskal-Wallis test is shown in panel C; similarly, no statistical differences were observed between groups when using Mann-Whitney U test (not shown). EC (n = 19); SC (n = 16); and NC (n = 21).